Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery

Background Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB). Methods Thrombi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of anesthesia 2016-06, Vol.30 (3), p.369-376
Hauptverfasser: Tanaka, Kenichi A., Mazzeffi, Michael A., Strauss, Erik R., Szlam, Fania, Guzzetta, Nina A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 376
container_issue 3
container_start_page 369
container_title Journal of anesthesia
container_volume 30
creator Tanaka, Kenichi A.
Mazzeffi, Michael A.
Strauss, Erik R.
Szlam, Fania
Guzzetta, Nina A.
description Background Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB). Methods Thrombin generation patterns were modeled in anticoagulated patients ( n  = 59) using a published computational model. Four dosing schemes were evaluated including single full dose (median, 41.2 IU/kg) of PCC before or after CPB, ½-dose before and after CPB, or 1/3-dose before CPB plus 2/3-dose after CPB. Hemodilution was modeled as 40 or 60 % dilution of factors from baseline. The lag time (s) of TG, and peak thrombin level (nM) were evaluated. Results Prolonged lag time, and reduced peak TG were due to low vitamin K-dependent (VKD) factors, and pre-CPB PCC dose-dependently restored TG to near-normal or normal range. After 40 % dilution, TG parameters were similar among 4 regimens at the end of therapy. The recovery of VKD factors was less when PCC was given before CPB after 60 % dilution, but TG parameters were considered hemostatically effective (>200 nM) with any regimen. Withholding the full dose of PCC until post-CPB resulted in severely depressed TG peak (median, 47 nM) after 60 % dilution, and some supra-normal TG peaks after treatment. Conclusions Pre-CPB administration of full or divided doses of PCC prevents extremely low TG peak during surgery, and maintains hemostatic TG peaks in both 40 and 60 % hemodilution models. Although PCC’s hemostatic activity appears to be highest using the full dose after CPB, hypercoagulability may develop in some cases.
doi_str_mv 10.1007/s00540-015-2128-3
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1791325455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A453191706</galeid><sourcerecordid>A453191706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-dc111406a7135d89398e966cd384279b085c32a296fa22255b1ddf3f169ad69c3</originalsourceid><addsrcrecordid>eNp9kk2LFDEQhoMo7rj6A7xIwMtees1HJ50cl0FXYcGLnkMmqcxm6U7GpFvdq7_czPYqCIPkUFTqeStU6kXoNSWXlJDhXSVE9KQjVHSMMtXxJ2hDe646xYV-ijZEU94pKdUZelHrHSFEUsqfozMmh173im3Qr22eDsts55iTHXGN0zI-JNgmj10r2hJrS3PAh5Ln25KnXUwPlRF-tpgcpLnYGbDPNaY9ru4WJqg45IJ_2BJag4QLfIdS2wtHrS0-WofrUvZQ7l-iZ8GOFV49xnP09cP7L9uP3c3n60_bq5vOCSnnzjtKaU-kHSgXXmmuFWgpneeqZ4PeESUcZ5ZpGSxjTIgd9T7wQKW2XmrHz9HF2rfN8W2BOpspVgfjaBPkpRo6tO9ioheioW9XdG9HMDGF3CZ0R9xc9YJTTQciG9WdoPaQoNgxJwixXf_DX57g2_EwRXdSQFeBK7nWAsEcSpxsuTeUmKMDzOoA0xxgjg4wvGnePE657CbwfxV_Vt4AtgK1lVJbgLnLS2nLr__p-htVn7xB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1791325455</pqid></control><display><type>article</type><title>Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Tanaka, Kenichi A. ; Mazzeffi, Michael A. ; Strauss, Erik R. ; Szlam, Fania ; Guzzetta, Nina A.</creator><creatorcontrib>Tanaka, Kenichi A. ; Mazzeffi, Michael A. ; Strauss, Erik R. ; Szlam, Fania ; Guzzetta, Nina A.</creatorcontrib><description>Background Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB). Methods Thrombin generation patterns were modeled in anticoagulated patients ( n  = 59) using a published computational model. Four dosing schemes were evaluated including single full dose (median, 41.2 IU/kg) of PCC before or after CPB, ½-dose before and after CPB, or 1/3-dose before CPB plus 2/3-dose after CPB. Hemodilution was modeled as 40 or 60 % dilution of factors from baseline. The lag time (s) of TG, and peak thrombin level (nM) were evaluated. Results Prolonged lag time, and reduced peak TG were due to low vitamin K-dependent (VKD) factors, and pre-CPB PCC dose-dependently restored TG to near-normal or normal range. After 40 % dilution, TG parameters were similar among 4 regimens at the end of therapy. The recovery of VKD factors was less when PCC was given before CPB after 60 % dilution, but TG parameters were considered hemostatically effective (&gt;200 nM) with any regimen. Withholding the full dose of PCC until post-CPB resulted in severely depressed TG peak (median, 47 nM) after 60 % dilution, and some supra-normal TG peaks after treatment. Conclusions Pre-CPB administration of full or divided doses of PCC prevents extremely low TG peak during surgery, and maintains hemostatic TG peaks in both 40 and 60 % hemodilution models. Although PCC’s hemostatic activity appears to be highest using the full dose after CPB, hypercoagulability may develop in some cases.</description><identifier>ISSN: 0913-8668</identifier><identifier>EISSN: 1438-8359</identifier><identifier>DOI: 10.1007/s00540-015-2128-3</identifier><identifier>PMID: 26749482</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Anesthesiology ; Anticoagulants - adverse effects ; Blood Coagulation - drug effects ; Blood Coagulation Factors - administration &amp; dosage ; Cardiac Surgical Procedures - methods ; Cardiopulmonary Bypass ; Comparative analysis ; Complications and side effects ; Computer Simulation ; Coronary artery bypass ; Critical Care Medicine ; Dosage and administration ; Emergency Medicine ; Humans ; Intensive ; Medicine ; Medicine &amp; Public Health ; Original Article ; Pain Medicine ; Patient outcomes ; Physiological aspects ; Prothrombin ; Thrombin - metabolism ; Warfarin ; Warfarin - adverse effects</subject><ispartof>Journal of anesthesia, 2016-06, Vol.30 (3), p.369-376</ispartof><rights>Japanese Society of Anesthesiologists 2016</rights><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-dc111406a7135d89398e966cd384279b085c32a296fa22255b1ddf3f169ad69c3</citedby><cites>FETCH-LOGICAL-c566t-dc111406a7135d89398e966cd384279b085c32a296fa22255b1ddf3f169ad69c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00540-015-2128-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00540-015-2128-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26749482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Mazzeffi, Michael A.</creatorcontrib><creatorcontrib>Strauss, Erik R.</creatorcontrib><creatorcontrib>Szlam, Fania</creatorcontrib><creatorcontrib>Guzzetta, Nina A.</creatorcontrib><title>Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery</title><title>Journal of anesthesia</title><addtitle>J Anesth</addtitle><addtitle>J Anesth</addtitle><description>Background Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB). Methods Thrombin generation patterns were modeled in anticoagulated patients ( n  = 59) using a published computational model. Four dosing schemes were evaluated including single full dose (median, 41.2 IU/kg) of PCC before or after CPB, ½-dose before and after CPB, or 1/3-dose before CPB plus 2/3-dose after CPB. Hemodilution was modeled as 40 or 60 % dilution of factors from baseline. The lag time (s) of TG, and peak thrombin level (nM) were evaluated. Results Prolonged lag time, and reduced peak TG were due to low vitamin K-dependent (VKD) factors, and pre-CPB PCC dose-dependently restored TG to near-normal or normal range. After 40 % dilution, TG parameters were similar among 4 regimens at the end of therapy. The recovery of VKD factors was less when PCC was given before CPB after 60 % dilution, but TG parameters were considered hemostatically effective (&gt;200 nM) with any regimen. Withholding the full dose of PCC until post-CPB resulted in severely depressed TG peak (median, 47 nM) after 60 % dilution, and some supra-normal TG peaks after treatment. Conclusions Pre-CPB administration of full or divided doses of PCC prevents extremely low TG peak during surgery, and maintains hemostatic TG peaks in both 40 and 60 % hemodilution models. Although PCC’s hemostatic activity appears to be highest using the full dose after CPB, hypercoagulability may develop in some cases.</description><subject>Anesthesiology</subject><subject>Anticoagulants - adverse effects</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation Factors - administration &amp; dosage</subject><subject>Cardiac Surgical Procedures - methods</subject><subject>Cardiopulmonary Bypass</subject><subject>Comparative analysis</subject><subject>Complications and side effects</subject><subject>Computer Simulation</subject><subject>Coronary artery bypass</subject><subject>Critical Care Medicine</subject><subject>Dosage and administration</subject><subject>Emergency Medicine</subject><subject>Humans</subject><subject>Intensive</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><subject>Prothrombin</subject><subject>Thrombin - metabolism</subject><subject>Warfarin</subject><subject>Warfarin - adverse effects</subject><issn>0913-8668</issn><issn>1438-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kk2LFDEQhoMo7rj6A7xIwMtees1HJ50cl0FXYcGLnkMmqcxm6U7GpFvdq7_czPYqCIPkUFTqeStU6kXoNSWXlJDhXSVE9KQjVHSMMtXxJ2hDe646xYV-ijZEU94pKdUZelHrHSFEUsqfozMmh173im3Qr22eDsts55iTHXGN0zI-JNgmj10r2hJrS3PAh5Ln25KnXUwPlRF-tpgcpLnYGbDPNaY9ru4WJqg45IJ_2BJag4QLfIdS2wtHrS0-WofrUvZQ7l-iZ8GOFV49xnP09cP7L9uP3c3n60_bq5vOCSnnzjtKaU-kHSgXXmmuFWgpneeqZ4PeESUcZ5ZpGSxjTIgd9T7wQKW2XmrHz9HF2rfN8W2BOpspVgfjaBPkpRo6tO9ioheioW9XdG9HMDGF3CZ0R9xc9YJTTQciG9WdoPaQoNgxJwixXf_DX57g2_EwRXdSQFeBK7nWAsEcSpxsuTeUmKMDzOoA0xxgjg4wvGnePE657CbwfxV_Vt4AtgK1lVJbgLnLS2nLr__p-htVn7xB</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Tanaka, Kenichi A.</creator><creator>Mazzeffi, Michael A.</creator><creator>Strauss, Erik R.</creator><creator>Szlam, Fania</creator><creator>Guzzetta, Nina A.</creator><general>Springer Japan</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160601</creationdate><title>Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery</title><author>Tanaka, Kenichi A. ; Mazzeffi, Michael A. ; Strauss, Erik R. ; Szlam, Fania ; Guzzetta, Nina A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-dc111406a7135d89398e966cd384279b085c32a296fa22255b1ddf3f169ad69c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anesthesiology</topic><topic>Anticoagulants - adverse effects</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation Factors - administration &amp; dosage</topic><topic>Cardiac Surgical Procedures - methods</topic><topic>Cardiopulmonary Bypass</topic><topic>Comparative analysis</topic><topic>Complications and side effects</topic><topic>Computer Simulation</topic><topic>Coronary artery bypass</topic><topic>Critical Care Medicine</topic><topic>Dosage and administration</topic><topic>Emergency Medicine</topic><topic>Humans</topic><topic>Intensive</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><topic>Prothrombin</topic><topic>Thrombin - metabolism</topic><topic>Warfarin</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Kenichi A.</creatorcontrib><creatorcontrib>Mazzeffi, Michael A.</creatorcontrib><creatorcontrib>Strauss, Erik R.</creatorcontrib><creatorcontrib>Szlam, Fania</creatorcontrib><creatorcontrib>Guzzetta, Nina A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Kenichi A.</au><au>Mazzeffi, Michael A.</au><au>Strauss, Erik R.</au><au>Szlam, Fania</au><au>Guzzetta, Nina A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery</atitle><jtitle>Journal of anesthesia</jtitle><stitle>J Anesth</stitle><addtitle>J Anesth</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>30</volume><issue>3</issue><spage>369</spage><epage>376</epage><pages>369-376</pages><issn>0913-8668</issn><eissn>1438-8359</eissn><abstract>Background Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB). Methods Thrombin generation patterns were modeled in anticoagulated patients ( n  = 59) using a published computational model. Four dosing schemes were evaluated including single full dose (median, 41.2 IU/kg) of PCC before or after CPB, ½-dose before and after CPB, or 1/3-dose before CPB plus 2/3-dose after CPB. Hemodilution was modeled as 40 or 60 % dilution of factors from baseline. The lag time (s) of TG, and peak thrombin level (nM) were evaluated. Results Prolonged lag time, and reduced peak TG were due to low vitamin K-dependent (VKD) factors, and pre-CPB PCC dose-dependently restored TG to near-normal or normal range. After 40 % dilution, TG parameters were similar among 4 regimens at the end of therapy. The recovery of VKD factors was less when PCC was given before CPB after 60 % dilution, but TG parameters were considered hemostatically effective (&gt;200 nM) with any regimen. Withholding the full dose of PCC until post-CPB resulted in severely depressed TG peak (median, 47 nM) after 60 % dilution, and some supra-normal TG peaks after treatment. Conclusions Pre-CPB administration of full or divided doses of PCC prevents extremely low TG peak during surgery, and maintains hemostatic TG peaks in both 40 and 60 % hemodilution models. Although PCC’s hemostatic activity appears to be highest using the full dose after CPB, hypercoagulability may develop in some cases.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>26749482</pmid><doi>10.1007/s00540-015-2128-3</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0913-8668
ispartof Journal of anesthesia, 2016-06, Vol.30 (3), p.369-376
issn 0913-8668
1438-8359
language eng
recordid cdi_proquest_miscellaneous_1791325455
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Anesthesiology
Anticoagulants - adverse effects
Blood Coagulation - drug effects
Blood Coagulation Factors - administration & dosage
Cardiac Surgical Procedures - methods
Cardiopulmonary Bypass
Comparative analysis
Complications and side effects
Computer Simulation
Coronary artery bypass
Critical Care Medicine
Dosage and administration
Emergency Medicine
Humans
Intensive
Medicine
Medicine & Public Health
Original Article
Pain Medicine
Patient outcomes
Physiological aspects
Prothrombin
Thrombin - metabolism
Warfarin
Warfarin - adverse effects
title Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A25%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computational%20simulation%20and%20comparison%20of%20prothrombin%20complex%20concentrate%20dosing%20schemes%20for%20warfarin%20reversal%20in%20cardiac%20surgery&rft.jtitle=Journal%20of%20anesthesia&rft.au=Tanaka,%20Kenichi%20A.&rft.date=2016-06-01&rft.volume=30&rft.issue=3&rft.spage=369&rft.epage=376&rft.pages=369-376&rft.issn=0913-8668&rft.eissn=1438-8359&rft_id=info:doi/10.1007/s00540-015-2128-3&rft_dat=%3Cgale_proqu%3EA453191706%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1791325455&rft_id=info:pmid/26749482&rft_galeid=A453191706&rfr_iscdi=true